Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Unichem Laboratories Ltd. Regulatory Filings 2026

Apr 12, 2026

61109_rns_2026-04-12_6bbcc1b4-e987-4b0b-8ea7-81f60ce13a7a.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

==> picture [190 x 43] intentionally omitted <==

12[th] April 2026

National Stock Exchange of India Limited BSE Limited Exchange Plaza, Listing Department Bandra Kurla Complex, P.J. Towers, 1[st] Floor, Bandra (E), Mumbai- 400051 Dalal Street, Fort, Mumbai – 400 001 Symbol: UNICHEMLAB Script Code: 506690

Symbol: UNICHEMLAB

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Unichem Pharmaceuticals (USA), Inc., a wholly-owned-subsidiary of the company has voluntarily recalled its products distributed in USA as under:

Product description Reason for recall
Buspirone Hydrochloride Tablets, USP
Strength: 5 mg
Pack size: 500 count bottles
Out-of-specification
(OOS)
assay
result
identified at the 12-month long-term stability
timepoint.

Unichem has not received any reports of any adverse events related to this recall to date. The Company places the highest priority on ensuring patient safety and maintaining product quality throughout every stage of its manufacturing and supply chain processes.

This is for your information and records.

Thanking you, For UNICHEM LABORATORIES LIMITED

==> picture [203 x 35] intentionally omitted <==

==> picture [48 x 47] intentionally omitted <==

PRADEEP BHANDARI Head – Legal & Company Secretary

==> picture [531 x 62] intentionally omitted <==